euro adhoc: Intercell AG / other / Intercell's Hepatitis C vaccine meets success criteria for further development - (Chronic Hepatitis C)

euro adhoc: Intercell AG / other / Intercell's Hepatitis C vaccine meets success criteria for further development -
Presseportal - Jan 31 8:59 AM
31.01.2006 Intercell (VSE; "ICLL") today announced initial data from a clinical trial aiming at the optimization of its therapeutic Hepatitis C vaccine IC41. Results ...Save to My Web

Hepatitis C recurs rapidly after liver transplant
EurekAlert! - Feb 02 6:56 AM
When a diseased liver is removed from a patient with Hepatitis C (HCV), serum viral levels plummet.Save to My Web

XTL Biopharmaceuticals to Present at the JPMorgan Small Cap Conference
[Press Release] PR Newswire via Yahoo! Finance - Feb 13 12:05 AM
XTL Biopharmaceuticals, Ltd. , a biopharmaceutical company developing drugs against hepatitis, announced today that Ron Bentsur, Chief Executive Officer, will present an overview of the Company at The JPMorgan Small Cap Conference in Philadelphia.Save to My Web

(AFX UK Focus) 2006-02-09 17:07 GMT: UK small caps end higher, Network Tech rallies, Hawtin up on stake build
Interactive Investor - Feb 09 9:35 AM
LONDON (AFX) - UK small caps end the session higher with Network Technology surging over 34 pct on news that it expects to reap the benefits of the tax relief in the second quarter of this year, while Hawtin's shares rally on news Gracelands Investments has increased its stake, dealers said.Save to My Web

BioCryst to Present at the BIO CEO & Investor Conference 2006
FinanzNachrichten - Feb 10 4:40 AM
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.Save to My Web